Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Exp Dermatol ; 36(3): 270-2, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20659118

RESUMEN

We present the case of a 79-year-old patient with extensive metastatic malignant melanoma (MM) of the scalp. Cutaneous MM of the head and neck often presents a therapeutic challenge. Radical surgical procedures and conventional chemotherapy are often unfeasible and contraindicated because of the difficult anatomy, the extent of the tumour process, and systemic toxicity. In our patient, selective intra-arterial perfusion with pegylated liposomal doxorubicin (PLD) and melphalan was performed after catheterization of both bilateral external carotid arteries with an arterial port system. PLD 4.5 mg/m(2) and melphalan (1.35 mg/m(2), followed by 2.7 mg/m(2) after reaching tolerance) were given as short-term infusions at two-weekly intervals into the right and left external carotid arteries, respectively. After eight applications with tolerable side-effects, no MM cells were detected; however, infiltrates of lymphocytes and melanophages were seen. This case suggests that intra-arterial chemotherapy may be a useful treatment for metastatic melanoma of the scalp.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de Cabeza y Cuello/secundario , Melanoma/secundario , Cuero Cabelludo , Neoplasias Cutáneas/tratamiento farmacológico , Anciano , Arteria Carótida Externa , Quimioterapia del Cáncer por Perfusión Regional/métodos , Doxorrubicina/administración & dosificación , Doxorrubicina/análogos & derivados , Femenino , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/patología , Humanos , Melanoma/tratamiento farmacológico , Melanoma/patología , Melfalán/administración & dosificación , Polietilenglicoles/administración & dosificación , Neoplasias Cutáneas/patología
2.
Br J Dermatol ; 161 Suppl 3: 85-9, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19775362

RESUMEN

BACKGROUND: Organ transplant recipients (OTRs) have an increased risk of developing skin cancer, especially epithelial tumours. A number of factors such as immunosuppression, age, ultraviolet radiation and skin type are considered as important in aetiology. OBJECTIVES: The purpose of this study was to further evaluate the risk factors for OTRs regarding skin cancer after transplantation. A detailed investigation of the specific compounds of sun exposure was realised. METHODS: A questionnaire-based study was performed in a specialist OTR dermatology clinic from January to April 2009. The subjects were 70 organ transplanted patients who had developed some form of skin cancer after transplantation. As controls served 69 organ transplanted patients who had no history of skin cancer. The controls were matched concerning age, transplanted organ and gender. Photo protection, sun exposure and transplantation data were part of the questionnaire. Statistical analysis was performed with Mann-Whitney-U-test, chi-square test or Fisher's exact test. RESULTS: The total sun burden (TSB) and the recreational sun exposure in particular attained higher scores in the skin cancer group (TSB-score: mean 11.8 vs. 10.0, P<0.05; recreational sun exposure: mean 6.3 vs. 5.1, P<0.05). The skin cancer group had fairer skin types than the control group (median skin type 2 vs. 3, P<0.05). The OTRs who developed skin cancer have been more likely to have a history or present intake of azathioprine (mean 42% vs. 21%, P<0.05). Also, the skin cancer group has been transplanted for a longer time (mean 12.3 vs. 7.2 years, P<0.001), analogously had a younger age at transplantation (mean 49.5 vs. 52.7 years, P<0.001). CONCLUSIONS: Recreational sun exposure is of central importance for OTRs. A long period of transplantation and thus immunosuppression presents a main risk factor for the development of skin cancer in OTRs. A multi disciplinary management with the best medication and a focus on sun protection is needed to prevent skin cancer in OTRs.


Asunto(s)
Huésped Inmunocomprometido , Neoplasias Inducidas por Radiación/etiología , Trasplante de Órganos , Neoplasias Cutáneas/etiología , Rayos Ultravioleta/efectos adversos , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Inducidas por Radiación/prevención & control , Cooperación del Paciente , Educación del Paciente como Asunto , Neoplasias Cutáneas/prevención & control , Pigmentación de la Piel/efectos de la radiación , Protectores Solares/administración & dosificación , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA